RICHMOND, Calif., Feb. 12, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the appointment of Heather D. Turner as senior vice president and general counsel, effective immediately. Ms. Turner will oversee all legal matters for the Company and will report to Sangamo's chief executive officer.
"I'm delighted to have Heather join Sangamo as we continue to expand the breadth of talent and experience on our leadership team," said Dr. Sandy Macrae, Sangamo's chief executive officer. "Her extensive legal and operational experience will serve Sangamo well as we advance our internal and external pipeline programs through late-stage development to commercialization."
Ms. Turner has over 18 years of experience advising public and private life science companies on various matters, including corporate governance, compliance, reporting, public reporting, public offering, mergers and acquisitions, and commercial, manufacturing and development contracts. Ms. Turner joins Sangamo from Atara Biotherapeutics, Inc., which she joined in 2015 and where she served as executive vice president, general counsel and secretary, and also, most recently, as head of portfolio strategy. From 2007 to 2015, she served as General Counsel and Secretary at Orexigen Therapeutics, Inc., where she led various general and administrative functions including compliance, risk management, legal, human resources and facilities. Earlier in her career, she worked as an associate in the corporate securities group at Cooley LLP.
Ms. Turner holds a J.D. from the University of California Los Angeles School of Law and is a member of the State Bar of California.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the Company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit www.sangamo.com.
SOURCE Sangamo Therapeutics, Inc.